Access Pharmaceuticals has presented its lead anticancer compound at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice and said it has few side effects.

The event, which took place last week in Valencia, saw the firm present is ProLindac compound which has shown to be active in a wide variety of solid tumours in both preclinical models and in human trials.

A study found that ProLindac was able to contribute to significant reductions in the specific serum marker Ca-125.

"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," said Jeffrey Davis, President and Chief Executive Officer of the firm.

"The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future," he explained.

Mr Davis also said that plans were being put together to look at multiple solid tumour types.

It is thought that the compound could eliminate some of the toxic side effects experienced by patients taking forms of the current DACH platinum drugs.



Source:

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium, 28/05/08
http://money.cnn.com/news/newsfeeds/articles/prnewswire/200805281000PR_NEWS_USPR_____LAW509.htm